%0 Journal Article %T Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology %A Alidousty, Christina %A Baar, Till %A Heydt, Carina %A Wagener-Ryczek, Svenja %A Kron, Anna %A Wolf, Juergen %A Buettner, Reinhard %A Schultheis, Anne Maria %J Journal of Thoracic Disease %D 2018 %B 2018 %9 %! Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology %K %X One distinct molecular subtype of non-small cell lung cancer (NSCLC) is defined by rearrangement of the anaplastic lymphoma kinase ( ALK ). The increasing knowledge over the last years has enabled the continuous improvement of ALK inhibitors; however, resistance in these patients remains a major concern. In this review, we summarize recent findings in ALK +-adenocarcinoma of the lung, highlighting the role of TP53 mutations in this specific cancer type and suggest new diagnostic strategies for the future, in order to improve patient’s outcome. %U https://jtd.amegroups.org/article/view/25843 %P S3-S8 %@ 2077-6624